{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:32:09Z","timestamp":1789104729141,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Progenics Pharmaceuticals","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"crossref","award":["CA134675, CA183031, CA184228, EB024495"],"award-info":[{"award-number":["CA134675, CA183031, CA184228, EB024495"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["701983"],"award-info":[{"award-number":["701983"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11307-019-01375-w","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T21:38:45Z","timestamp":1559079525000},"page":"190-197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake"],"prefix":"10.1007","volume":"22","author":[{"given":"Rudolf A.","family":"Werner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Bundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Bundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrbod S.","family":"Javadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Pienta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Lodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Gorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"key":"1375_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/bju.13435","volume":"117","author":"MA Gorin","year":"2016","unstructured":"Gorin MA, Pomper MG, Rowe SP (2016) PSMA-targeted imaging of prostate cancer: the best is yet to come. BJU Int 117:715\u2013716","journal-title":"BJU Int"},{"key":"1375_CR2","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00259-017-3780-7","volume":"44","author":"S Sheikhbahaei","year":"2017","unstructured":"Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, Pienta KJ, Allaf ME, Haberkorn U, Pomper MG, Gorin MA, Rowe SP (2017) Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging 44:2117\u20132136","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1375_CR3","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.eururo.2016.07.045","volume":"70","author":"M Eiber","year":"2016","unstructured":"Eiber M, Herrmann K, Fendler WP, Maurer T (2016) 68Ga-labeled prostate-specific membrane antigen positron emission tomography for prostate cancer imaging: the new kid on the block-early or too early to draw conclusions? Eur Urol 70:938\u2013940","journal-title":"Eur Urol"},{"key":"1375_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2967\/jnumed.117.190157","volume":"58","author":"C Kesch","year":"2017","unstructured":"Kesch C, Kratochwil C, Mier W, Kopka K, Giesel FL (2017) 68Ga or 18F for prostate cancer imaging? J Nucl Med 58:687\u2013688","journal-title":"J Nucl Med"},{"key":"1375_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","volume":"17","author":"Z Szabo","year":"2015","unstructured":"Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC, Vranesic M, Bhatnagar A, Sgouros G, Cho SY, Pomper MG (2015) Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol 17:565\u2013574","journal-title":"Mol Imaging Biol"},{"key":"1375_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","volume":"17","author":"M Dietlein","year":"2015","unstructured":"Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schom\u00e4cker K, Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R, Neubauer S, Drzezga A, Neumaier B (2015) Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol 17:575\u2013584","journal-title":"Mol Imaging Biol"},{"key":"1375_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.urology.2018.03.030","volume":"117","author":"RA Werner","year":"2018","unstructured":"Werner RA, Andree C, Javadi MS, Lapa C, Buck AK, Higuchi T, Pomper MG, Gorin MA, Rowe SP, Pienta KJ (2018) A voice from the past: rediscovering the virchow node with prostate-specific membrane antigen-targeted 18F-DCFPyL positron emission tomography imaging. Urology 117:18\u201321","journal-title":"Urology"},{"key":"1375_CR8","doi-asserted-by":"publisher","first-page":"6088","DOI":"10.7150\/thno.30357","volume":"8","author":"RA Werner","year":"2018","unstructured":"Werner RA, Weich A, Kircher M, Solnes LB, Javadi MS, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C (2018) The theranostic promise for neuroendocrine tumors in the late 2010s - where do we stand, where do we go? Theranostics 8:6088\u20136100","journal-title":"Theranostics"},{"key":"1375_CR9","first-page":"61","volume":"54","author":"V Prasad","year":"2010","unstructured":"Prasad V, Baum RP (2010) Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging 54:61\u201367","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"1375_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/RLU.0b013e318208f503","volume":"36","author":"Y Liu","year":"2011","unstructured":"Liu Y (2011) Super-superscan on a bone scintigraphy. Clin Nucl Med 36:227\u2013228","journal-title":"Clin Nucl Med"},{"key":"1375_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00259-011-1937-3","volume":"39","author":"JM Beauregard","year":"2012","unstructured":"Beauregard JM, Hofman MS, Kong G, Hicks RJ (2012) The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 39:50\u201356","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1375_CR12","doi-asserted-by":"crossref","unstructured":"Werner RA, Hanscheid H, Leal JP et al (2018) Impact of tumor burden on quantitative [68Ga] DOTATATE biodistribution. Mol Imaging Biol.In Press.","DOI":"10.1007\/s11307-018-1293-9"},{"key":"1375_CR13","doi-asserted-by":"publisher","first-page":"55094","DOI":"10.18632\/oncotarget.19049","volume":"8","author":"FC Gaertner","year":"2017","unstructured":"Gaertner FC, Halabi K, Ahmadzadehfar H, K\u00fcrpig S, Eppard E, Kotsikopoulos C, Liakos N, Bundschuh RA, Strunk H, Essler M (2017) Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget 8:55094\u201355103","journal-title":"Oncotarget"},{"key":"1375_CR14","doi-asserted-by":"crossref","unstructured":"Sahakyan K, Li X, Lodge MA, et al. (2019) Semiquantitative parameters in PSMA-targeted PET imaging with 18F-DCFPyL: intrapatient and interpatient variability of normal organ uptake. Mol Imaging Biol. In Press.","DOI":"10.1007\/s11307-019-01376-9"},{"key":"1375_CR15","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2967\/jnumed.118.217588","volume":"59","author":"RA Werner","year":"2018","unstructured":"Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Leal JP, Higuchi T, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP (2018) Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET\/CT imaging. J Nucl Med 59:1857\u20131864","journal-title":"J Nucl Med"},{"key":"1375_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/jlcr.3430","volume":"59","author":"HT Ravert","year":"2016","unstructured":"Ravert HT, Holt DP, Chen Y, Mease RC, Fan H, Pomper MG, Dannals RF (2016) An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [18F]DCFPyL. J Label Comp Radiopharm 59:439\u2013450","journal-title":"J Label Comp Radiopharm"},{"key":"1375_CR17","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s12149-017-1201-4","volume":"31","author":"RA Werner","year":"2017","unstructured":"Werner RA, Sheikhbahaei S, Jones KM, Javadi MS, Solnes LB, Ross AE, Allaf ME, Pienta KJ, Lapa C, Buck AK, Higuchi T, Pomper MG, Gorin MA, Rowe SP (2017) Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL in peripheral ganglia. Ann Nucl Med 31:696\u2013702","journal-title":"Ann Nucl Med"},{"key":"1375_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.eururo.2017.10.027","volume":"73","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA (2018) PSMA-RADS version 1.0: a step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies. Eur Urol 73:485\u2013487","journal-title":"Eur Urol"},{"key":"1375_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2967\/jnumed.117.195255","volume":"59","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA (2018) Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0. J Nucl Med 59:479\u2013485","journal-title":"J Nucl Med"},{"key":"1375_CR20","doi-asserted-by":"publisher","first-page":"942","DOI":"10.2967\/jnumed.116.179739","volume":"58","author":"X Li","year":"2017","unstructured":"Li X, Rowe SP, Leal JP, Gorin MA, Allaf ME, Ross AE, Pienta KJ, Lodge MA, Pomper MG (2017) Semiquantitative parameters in PSMA-targeted PET imaging with (18)F-DCFPyL: variability in normal-organ uptake. J Nucl Med 58:942\u2013946","journal-title":"J Nucl Med"},{"key":"1375_CR21","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s00259-018-4042-z","volume":"45","author":"C Schmidkonz","year":"2018","unstructured":"Schmidkonz C, Cordes M, Schmidt D, B\u00e4uerle T, Goetz TI, Beck M, Prante O, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P (2018) 68Ga-PSMA-11 PET\/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging 45:1862\u20131872","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1375_CR22","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.2967\/jnumed.117.193581","volume":"58","author":"S Schmuck","year":"2017","unstructured":"Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T (2017) Initial experience with volumetric 68Ga-PSMA I&T PET\/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med 58:1962\u20131968","journal-title":"J Nucl Med"},{"key":"1375_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","volume":"18","author":"SP Rowe","year":"2016","unstructured":"Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, Eisenberger M, Carducci M, Fan H, Dannals RF, Chen Y, Mease RC, Szabo Z, Pomper MG, Cho SY (2016) PSMA-based [18F]DCFPyL PET\/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol 18:411\u2013419","journal-title":"Mol Imaging Biol"},{"key":"1375_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.117.193706","volume":"59","author":"H Hanscheid","year":"2018","unstructured":"Hanscheid H, Lapa C, Buck AK, Lassmann M, Werner RA (2018) Dose mapping after endoradiotherapy with 177Lu-DOTATATE\/DOTATOC by a single measurement after 4 days. J Nucl Med 59:75\u201381","journal-title":"J Nucl Med"},{"key":"1375_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3413\/Nukmed-0925-17-08","volume":"56","author":"H Hanscheid","year":"2017","unstructured":"Hanscheid H, Lapa C, Buck AK, Lassmann M, Werner RA (2017) Absorbed dose estimates from a single measurement one to three days after the administration of 177Lu-DOTATATE\/-TOC. Nuklearmedizin 56:219\u2013224","journal-title":"Nuklearmedizin"},{"key":"1375_CR26","doi-asserted-by":"publisher","first-page":"97S","DOI":"10.2967\/jnumed.116.186841","volume":"58","author":"U Eberlein","year":"2017","unstructured":"Eberlein U, Cremonesi M, Lassmann M (2017) Individualized dosimetry for theranostics: necessary, nice to have, or counterproductive? J Nucl Med 58:97S\u2013103S","journal-title":"J Nucl Med"},{"key":"1375_CR27","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.118.212233","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, Neels O, Schiller K, Amaral H, Weber WA, Haberkorn U, Schwaiger M, Kratochwil C, Choyke P, Kramer V, Kopka K, Eiber M (2019) Detection efficacy of 18F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med 60:362\u2013368","journal-title":"J Nucl Med"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-019-01375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11307-019-01375-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-019-01375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T23:33:53Z","timestamp":1590536033000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11307-019-01375-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1375"],"URL":"https:\/\/doi.org\/10.1007\/s11307-019-01375-w","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,28]]},"assertion":[{"value":"28 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Martin G. Pomper is a coinventor on a patent covering [<sup>18<\/sup>F]DCFPyL and is entitled to a portion of any licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. He has also received research funding from Progenics Pharmaceuticals, the licensee of [<sup>18<\/sup>F]DCFPyL. Michael A. Gorin has served as a consultant to, and has received research funding from, Progenics Pharmaceuticals. Kenneth J. Pienta has received research funding from Progenics Pharmaceuticals. Steven P. Rowe has received research funding from Progenics Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}